Quinolinic acid Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 970

Clinical Trials

Several clinical trials investigate conditions and biological processes associated with kynurenine pathway signaling and tryptophan metabolites, focusing on therapeutic areas such as delayed graft function, acute kidney injury, adult migraine disorders, and pediatric migraine. The landscape encompasses Phase II, Phase III, and observational designs sponsored by academic medical centers and public research institutions. Recruitment statuses across these protocols include completed, actively recruiting, and not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05513807	Not yet recruiting	Delayed Graft Function	Assistance Publique - Hôpitaux de Paris\|Institut National de la Santé Et de la Recherche Médicale France\|Centre National de la Recherche Scientifique France	2022-11	Phase 3
NCT05718310	Recruiting	Migraine\|Migraine Disorders\|Pain	IRCCS National Neurological Institute C. Mondino Foundation\|University of Pavia	2022-11-01	Not Applicable
NCT05969990	Recruiting	Migraine in Children	Qilu Hospital of Shandong University	2022-01-01	--
NCT04342975	Completed	AKI	Mayo Clinic\|Elysium Health	2020-12-01	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Quinolinic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Quinolinic acid selectively binds and activates N-methyl-D-aspartate (NMDA) receptors, triggering excessive ion channel opening and downstream intracellular calcium influx within vulnerable neuronal populations. This persistent calcium overload leads to cellular excitotoxicity and metabolic dysfunction, providing a pathophysiological mechanism relevant to clinical studies exploring neurovascular and ischemic conditions such as migraine disorders and acute kidney injury.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).